clinical trial · NCT05127486
A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine
Eli Lilly and Company·phase4·completed·n = 580
MigraineEpisodic MigraineGalcanezumabRimegepantPlaceboPlacebo
brief summary
The purpose of this study is to assess whether galcanezumab is superior to rimegepant in the prevention of migraine in participants with episodic migraine. The study duration will be approximately 6 months.
started
Dec 6, 2021
primary completion
May 23, 2023
completion
May 23, 2023
last updated
Jun 28, 2024
official title
A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants With Episodic Migraine
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol